Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2008

Saudi Arabia Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Saudi Arabia's pharmaceuticals and healthcare industry.

Saudi Arabia’s drug market is the largest in the Gulf Cooperation Council (GCC). Estimates that drug expenditure was SAR8.52bn (US$2.27bn) in 2007. Over the forecast period (2008-2012) we expect the market to grow at an average rate of 6.8% annually to reach a value of SAR11.83bn (US$5bn) by the end of 2012.

Although a strict pricing environment should hold down pharmaceutical price inflation, we expect higher consumption volumes to drive growth over the forecast period. Epidemiological trends should also increase demand for pharmaceuticals. The recently launched Burden of Disease Database (BoDD) forecasts that the overall disease and injury burden should continue to grow between 2008 and 2030. The total number of disability-adjusted life years (DALYs) lost to disease and injury annually should rise at an average rate of 0.79% a year from 3.2mn DALYs lost in 2007 to 3.8mn DALYs lost in 2030.

In the updated Business Environment Ratings for Q408, Saudi Arabia receives an improved score of 50 out of 100, placing it equal fifth out of 15 Middle East and Africa markets surveyed. Although the pharmaceutical-specific risks remain relatively high, the country’s political risks have reduced on account of an improved economic structure. In part, this is due to the high price of oil stimulating an improved trade balance.

The country’s US$448mn medical device market continues to suffer from a lack of regulation. However, this should be remedied in the near future as the Saudi Food and Drug Authority (SFDA) has been tasked with drafting guidelines.

Despite heavy investment in public health infrastructure, a shortage of beds in government hospitals has seemingly worsened in 2008. In response to a shortage of intensive care beds at government hospitals, the government pledged to pay the private hospital fees for these services if they are unavailable at public hospitals. The decision was reported in the Alsharq Al-Awsat newspaper in January 2008. This was extended to emergency patients in May. SHOW LESS READ MORE >

"Executive Summary
Table: Saudi Arabia Pharmaceuticals And Healthcare SW
Table: Saudi Arabia Political SWOT
Table: Saudi Arabia Economic SWOT
Table: Saudi Arabia Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Middle East And Africa Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Saudi Arabia – Market Summary
Regulatory Regime
Regional Regulatory Developments
Free Trade Agreements
Intellectual Property Developments
IP Deficiencies
Pricing And Reimbursement Issues
Tendering Procedures
Table: Saudi Arabia’s Import Margins
Industry Developments
Epidemiology
HIV/AIDS
Healthcare Sector
Primary Healthcare Provision
Secondary Healthcare Provision
Recent Healthcare Provision Developments
Health Insurance
Pharmaceutical Sector
Pharmaceutical Distribution Sector
Table: Leading Saudi Arabian Drug Distribution Firms
Recent Pharmaceutical Company Activities
Industry Forecast Scenario
Key Growth Factors – Industry
Table: Saudi Arabian Health Expenditure Indicators, 2006-2012
Overall Market Forecasts
Table: Saudi Arabian’s Drug Market Indicators, 2006-2012 (US$mn unless otherwise stated)
Macroeconomic Scenario
Economic Activity
Table: Saudi Arabia – Economic Activity
Patented Drug Market Forecast
Generics Market Forecast
Table: Saudi Arabia’s Generics Market, 2006-2012
OTC Market Forecast
Table: Saudi Arabia OTC Market, 2006-2012 (US$mn unless otherwise stated)
Table: Saudi Arabia’s Medical Device Market, 2005-2012 (US$mn unless otherwise stated)
Pharmaceutical Export/Import Market Forecasts
Table: Saudi Arabia’s Pharmaceutical Export/Import Fo
Other Healthcare Data Forecasts
Table: Saudi Arabia’s Other Healthcare Data And Foreca
Key Risks To BMI Forecasts
Competitive Landscape
Table: Leading Pharmaceutical Companies In Saudi Arabia
Table: Leading Products By Value In Private Saudi Arabian Pharmaceutical Market, Q406 (MAT)
Company Profiles
Multinational Company Profiles
GlaxoSmithKline
Novartis
Merck & Co
Pfizer
Sanofi-Aventis
Indigenous Company Profiles
Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO)
Saudi Arabian Japanese Pharmaceutical (SAJA)
TABUK Pharmaceutical Manufacturing
Al Jazeera Pharmaceutical Industries (JPI)
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources

- GlaxoSmithKline
- Novartis
- Merck & Co
- Pfizer
- Sanofi-Aventis